US6083903A
(en)
*
|
1994-10-28 |
2000-07-04 |
Leukosite, Inc. |
Boronic ester and acid compounds, synthesis and uses
|
US6838477B2
(en)
*
|
1995-04-12 |
2005-01-04 |
President And Fellows Of Harvard College |
Lactacystin analogs
|
FR2758329B1
(fr)
*
|
1997-01-16 |
1999-02-12 |
Synthelabo |
Derives d'imidazole-4-butane boronique, leur preparation et leur utilisation en therapeutique
|
CN1159061C
(zh)
|
1997-02-15 |
2004-07-28 |
千年药物公司 |
通过nf-kappab的抑制治疗梗塞
|
US6221888B1
(en)
*
|
1997-05-29 |
2001-04-24 |
Merck & Co., Inc. |
Sulfonamides as cell adhesion inhibitors
|
EP1017398A1
(en)
*
|
1997-09-25 |
2000-07-12 |
Proscript, Inc. |
Proteasome inhibitors, ubiquitin pathway inhibitors or agents that interfere with the activation of nf-kb via the ubiquitin proteasome pathway to treat inflammatory and autoimmune diseases
|
ES2285785T3
(es)
*
|
1997-09-29 |
2007-11-16 |
Point Therapeutics, Inc. |
Estimulacion de celulas hematopoyeticas in vitro.
|
US6831057B2
(en)
*
|
1997-10-28 |
2004-12-14 |
The University Of North Carolina At Chapel Hill |
Use of NF-κB inhibition in combination therapy for cancer
|
CA2219867A1
(en)
*
|
1997-10-31 |
1999-04-30 |
Jiangping Wu |
The use of proteasome inhibitors for treating cancer, inflammation, autoimmune disease, graft rejection and septic shock
|
DE19802450A1
(de)
*
|
1998-01-23 |
1999-07-29 |
Hoechst Marion Roussel De Gmbh |
Ustilipide, Verfahren zu deren Herstellung sowie deren Verwendung
|
US6075150A
(en)
|
1998-01-26 |
2000-06-13 |
Cv Therapeutics, Inc. |
α-ketoamide inhibitors of 20S proteasome
|
US6617171B2
(en)
*
|
1998-02-27 |
2003-09-09 |
The General Hospital Corporation |
Methods for diagnosing and treating autoimmune disease
|
FR2779653B1
(fr)
*
|
1998-06-11 |
2002-12-20 |
Inst Nat Sante Rech Med |
Utilisation de composes modulateurs du proteasome en therapie
|
US6838436B1
(en)
*
|
1998-07-10 |
2005-01-04 |
Osteoscreen Inc. |
Inhibitors of proteasomal activity for stimulating bone growth
|
US6902721B1
(en)
*
|
1998-07-10 |
2005-06-07 |
Osteoscreen, Inc. |
Inhibitors of proteasomal activity for stimulating bone growth
|
US6462019B1
(en)
*
|
1998-07-10 |
2002-10-08 |
Osteoscreen, Inc. |
Inhibitors of proteasomal activity and production for stimulating bone growth
|
US6979697B1
(en)
*
|
1998-08-21 |
2005-12-27 |
Point Therapeutics, Inc. |
Regulation of substrate activity
|
EP0982317A1
(en)
*
|
1998-08-26 |
2000-03-01 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Bivalent inhibitors of the proteasome
|
NZ511197A
(en)
*
|
1998-10-20 |
2003-08-29 |
Millenium Pharmaceuticals Inc |
Method for monitoring proteasome inhibitor drug action
|
US6492333B1
(en)
*
|
1999-04-09 |
2002-12-10 |
Osteoscreen, Inc. |
Treatment of myeloma bone disease with proteasomal and NF-κB activity inhibitors
|
US6890904B1
(en)
*
|
1999-05-25 |
2005-05-10 |
Point Therapeutics, Inc. |
Anti-tumor agents
|
US6649593B1
(en)
*
|
1999-10-13 |
2003-11-18 |
Tularik Inc. |
Modulators of SREBP processing
|
US20040039129A1
(en)
*
|
2000-08-16 |
2004-02-26 |
Hall Dennis G. |
Non-pressurized methods for the preparation of conjugrated solid supports for boronic acids
|
US6919382B2
(en)
|
2000-08-31 |
2005-07-19 |
The Governors Of The University Of Alberta |
Preparation and uses of conjugated solid supports for boronic acids
|
DK1326632T3
(da)
*
|
2000-10-12 |
2007-01-15 |
Viromics Gmbh |
Protease-inhibitorer til behandling af infektioner af hepatitisvirus
|
JP4162491B2
(ja)
|
2001-01-25 |
2008-10-08 |
アメリカ合衆国 |
ボロン酸化合物製剤
|
US7112588B2
(en)
*
|
2001-05-21 |
2006-09-26 |
Alcon, Inc. |
Use of proteasome inhibitors to treat dry eye disorders
|
DK1392355T3
(da)
|
2001-05-21 |
2007-04-30 |
Alcon Inc |
Anvendelse af proteasominhibitorer tilbehandling af öjentörhedslidelser
|
CN100415770C
(zh)
*
|
2001-05-30 |
2008-09-03 |
诺瓦提斯公司 |
2-{[n-(2-氨基-3-(杂芳基或芳基)丙酰基)-氨基酰基]-氨基}-烷基硼酸衍生物
|
WO2003033506A1
(fr)
*
|
2001-10-12 |
2003-04-24 |
Kyorin Pharmaceutical Co., Ltd. |
Derive d'acide d'aminoborane et medicament inhibiteur de proteasomes le contenant
|
WO2003033507A1
(fr)
*
|
2001-10-12 |
2003-04-24 |
Kyorin Pharmaceutical Co., Ltd. |
Derives d'acide benzylmalonique et inhibiteurs de proteasomes les contenant
|
US7524883B2
(en)
|
2002-01-08 |
2009-04-28 |
Eisai R&D Management Co., Ltd. |
Eponemycin and epoxomicin analogs and uses thereof
|
WO2003077928A1
(en)
*
|
2002-03-12 |
2003-09-25 |
Ariad Pharmaceuticals, Inc. |
Peptide analogues and uses thereof
|
US7501417B2
(en)
|
2002-03-13 |
2009-03-10 |
Janssen Pharmaceutica, N.V. |
Aminocarbonyl-derivatives as novel inhibitors of histone deacetylase
|
DK1485348T3
(da)
|
2002-03-13 |
2008-09-29 |
Janssen Pharmaceutica Nv |
Carbonylamino-derivater som nye inhibitorer af histandeacetylase
|
AU2003218735B2
(en)
*
|
2002-03-13 |
2009-03-12 |
Janssen Pharmaceutica N.V. |
Piperazinyl-, piperidinyl- and morpholinyl-derivatives as novel inhibitors of histone deacetylase
|
PL214279B1
(pl)
|
2002-03-13 |
2013-07-31 |
Janssen Pharmaceutica Nv |
Pochodna sulfonyloaminowa, sposób jej wytwarzania i zastosowanie oraz kompozycja farmaceutyczna i sposób jej wytwarzania
|
DE10391147D2
(de)
*
|
2002-04-05 |
2005-02-17 |
Viromics Gmbh |
Mittel zur Behandlung von Flaviviridae-Infektionen
|
US7514579B2
(en)
*
|
2002-06-13 |
2009-04-07 |
Johns Hopkins University |
Boronic chalcone derivatives and uses thereof
|
CA2491474A1
(en)
*
|
2002-07-09 |
2004-01-15 |
Point Therapeutics, Inc. |
Boroproline compound combination therapy
|
JP2005539028A
(ja)
*
|
2002-08-14 |
2005-12-22 |
ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ |
乳腺炎の処置のためのnf−カッパbインヒビターの使用
|
US20050176651A1
(en)
*
|
2002-09-09 |
2005-08-11 |
Trigen Limited |
Peptide boronic acids useful in making salts thereof
|
US20050119226A1
(en)
*
|
2003-09-09 |
2005-06-02 |
Trigen Limited |
Methods for synthesizing organoboronic compounds and products thereof
|
US20050282757A1
(en)
*
|
2002-09-09 |
2005-12-22 |
Trigen Limited |
Peptide boronic acid compounds useful in anticoagulation
|
US7112572B2
(en)
*
|
2002-09-09 |
2006-09-26 |
Trigen Limited |
Multivalent metal salts of boronic acids
|
US20060084592A1
(en)
*
|
2002-09-09 |
2006-04-20 |
Trigen Limited |
Peptide boronic acid inhibitors
|
MXPA05002661A
(es)
*
|
2002-09-09 |
2005-08-19 |
Trigen Ltd |
Sales de acido boronico y su uso en el tratamiento de trombosis.
|
EP1542768A1
(en)
*
|
2002-09-20 |
2005-06-22 |
Alcon, Inc. |
Use of cytokine synthesis inhibitors for the treatment of dry eye disorders
|
ES2542328T3
(es)
|
2002-12-06 |
2015-08-04 |
Millennium Pharmaceuticals, Inc. |
Métodos para la identificación, evaluación y tratamiento de pacientes con terapia de inhibición del proteasoma
|
CN100341880C
(zh)
*
|
2003-02-13 |
2007-10-10 |
上海仁虎制药股份有限公司 |
新型硼酸或硼酸酯类化合物、制备方法及在药学上的应用
|
WO2005007211A2
(en)
*
|
2003-07-03 |
2005-01-27 |
Medtronic Vascular Inc. |
Medical devices with proteasome inhibitors for the treatment of restenosis
|
US7576206B2
(en)
*
|
2003-08-14 |
2009-08-18 |
Cephalon, Inc. |
Proteasome inhibitors and methods of using the same
|
US7223745B2
(en)
*
|
2003-08-14 |
2007-05-29 |
Cephalon, Inc. |
Proteasome inhibitors and methods of using the same
|
WO2005044998A2
(en)
|
2003-11-05 |
2005-05-19 |
Palingen, Inc. |
Enhanced b cell cytotoxicity of cdim binding antibody
|
US20060052390A1
(en)
*
|
2003-12-24 |
2006-03-09 |
Scios, Inc. |
Treatment of multiple myeloma by p38 MAP kinase and proteasome inhibition
|
KR101292707B1
(ko)
*
|
2004-02-23 |
2013-08-02 |
트러스티즈 오브 터프츠 칼리지 |
디펩티딜펩티다아제 ⅳ의 억제제
|
GB0405272D0
(en)
*
|
2004-03-09 |
2004-04-21 |
Trigen Ltd |
Compounds
|
US7371875B2
(en)
*
|
2004-03-12 |
2008-05-13 |
Miikana Therapeutics, Inc. |
Cytotoxic agents and methods of use
|
RS51983B
(en)
|
2004-03-30 |
2012-02-29 |
Millennium Pharmaceuticals Inc. |
SYNTHESIS OF ORGANOBORIC ACID AND ORGANOBORIC ACID COMPOUNDS
|
AU2016202747B2
(en)
*
|
2004-03-30 |
2017-11-23 |
Millennium Pharmaceuticals, Inc. |
Synthesis of boronic ester and acid compounds
|
SG185306A1
(en)
|
2004-04-15 |
2012-11-29 |
Onyx Therapeutics Inc |
Compounds for proteasome enzyme inhibition
|
US8198270B2
(en)
|
2004-04-15 |
2012-06-12 |
Onyx Therapeutics, Inc. |
Compounds for proteasome enzyme inhibition
|
US8088741B2
(en)
|
2004-05-10 |
2012-01-03 |
Onyx Therapeutics, Inc. |
Compounds for enzyme inhibition
|
EP2277595A3
(en)
|
2004-06-24 |
2011-09-28 |
Novartis Vaccines and Diagnostics, Inc. |
Compounds for immunopotentiation
|
JP2008507541A
(ja)
|
2004-07-23 |
2008-03-13 |
ロイヤルティ,スーザン・マリー |
ペプチダーゼ阻害剤
|
KR101261305B1
(ko)
|
2004-07-28 |
2013-05-08 |
얀센 파마슈티카 엔.브이. |
히스톤 디아세틸라제의 신규한 저해제로의 치환된 인돌릴알킬 아미노 유도체
|
CA2584515A1
(en)
|
2004-10-20 |
2006-04-27 |
Proteolix, Inc. |
Labeled compounds for proteasome inhibition
|
TW200618820A
(en)
*
|
2004-11-05 |
2006-06-16 |
Alza Corp |
Liposome formulations of boronic acid compounds
|
MX2007005320A
(es)
|
2004-11-05 |
2007-11-12 |
Palingen Inc |
Herida de la membrana celular inducida por anticuerpo.
|
US8017395B2
(en)
|
2004-12-17 |
2011-09-13 |
Lifescan, Inc. |
Seeding cells on porous supports
|
US20070098685A1
(en)
*
|
2005-01-19 |
2007-05-03 |
Brand Stephen J |
Methods and kits to treat chronic inflammatory immune diseases by administering a proteasome inhibitor and an interleukin 2 receptor agonist
|
US20090036435A1
(en)
|
2005-01-21 |
2009-02-05 |
Astex Therapeutics Limited |
Pharmaceutical Compounds
|
US20090018146A1
(en)
*
|
2005-01-27 |
2009-01-15 |
Research Development Corporation |
Combination Therapy with Triterpenoid Compounds and Proteasome Inhibitors
|
US7468383B2
(en)
*
|
2005-02-11 |
2008-12-23 |
Cephalon, Inc. |
Proteasome inhibitors and methods of using the same
|
ES2540966T3
(es)
|
2005-02-16 |
2015-07-15 |
Anacor Pharmaceuticals, Inc. |
Compuestos biocidas de boronoftalida
|
US7589066B2
(en)
*
|
2005-03-11 |
2009-09-15 |
The University Of North Carolina At Chapel Hill |
Potent and specific immunoproteasome inhibitors
|
US20060252740A1
(en)
*
|
2005-04-29 |
2006-11-09 |
Johnson Robert G Jr |
Method of treating multiple myeloma using 17-AAG or 17-AG or a prodrug of either in combination with a proteasome inhibitor
|
DK1885710T3
(en)
|
2005-05-18 |
2015-11-23 |
Janssen Pharmaceutica Nv |
SUBSTITUTED AMINOPROPENYLPIPERIDINE OR MORPHOLINE DERIVATIVES AS UNKNOWN INHIBITORS OF HISTONDEACETYLASE
|
AU2006202209B2
(en)
*
|
2005-05-27 |
2011-04-14 |
Lifescan, Inc. |
Amniotic fluid derived cells
|
CA2613889A1
(en)
*
|
2005-06-08 |
2006-12-14 |
Centocor, Inc. |
A cellular therapy for ocular degeneration
|
US20090017006A1
(en)
*
|
2005-07-06 |
2009-01-15 |
Biodevelops Pharma Entwicklung Gmbh |
Use of a compound for enhancing the expression of membrane proteins on the cell surface
|
US7531517B2
(en)
|
2005-08-10 |
2009-05-12 |
4Sc Ag |
Inhibitors of cancer cell, T-cell and keratinocyte proliferation
|
EP1752467A1
(en)
|
2005-08-10 |
2007-02-14 |
4Sc Ag |
Inhibitors of cancer cell, t-cell and keratinocyte proliferation
|
US20070059382A1
(en)
*
|
2005-09-09 |
2007-03-15 |
Board Of Regents, Univ. And Comm. College System Of Nevada... |
Medical treatment of breast cancer with boric acid materials
|
PL2623113T3
(pl)
|
2005-11-09 |
2018-05-30 |
Onyx Therapeutics, Inc. |
Związek do hamowania enzymu
|
EP1956908A2
(en)
*
|
2005-12-08 |
2008-08-20 |
Cytokinetics, Inc. |
Certain compositions and methods of treatment
|
BRPI0621279B1
(pt)
|
2005-12-30 |
2021-07-20 |
Anacor Pharmaceuticals, Inc |
Moléculas pequenas contendo boro
|
JP5137848B2
(ja)
*
|
2006-01-19 |
2013-02-06 |
ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ |
ヒストンデアセチラーゼのインヒビターとしてのピリジン及びピリミジン誘導体
|
JP5225104B2
(ja)
*
|
2006-01-19 |
2013-07-03 |
ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ |
新しい、ヒストンデアセチラーゼのインヒビターとしてのアミノフェニル誘導体
|
AU2007206950B2
(en)
*
|
2006-01-19 |
2012-02-02 |
Janssen Pharmaceutica N.V. |
Substituted indolyl-alkyl-amino-derivatives as inhibitors of histone deacetylase
|
AU2007206942B2
(en)
|
2006-01-19 |
2012-08-23 |
Janssen Pharmaceutica N.V. |
Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase
|
JO2660B1
(en)
|
2006-01-20 |
2012-06-17 |
نوفارتيس ايه جي |
Pi-3 inhibitors and methods of use
|
PE20070978A1
(es)
*
|
2006-02-14 |
2007-11-15 |
Novartis Ag |
COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks)
|
DK2719388T3
(da)
|
2006-02-16 |
2019-05-13 |
Anacor Pharmaceuticals Inc |
Borholdige små molekyler som antiinflammatoriske midler
|
TW200808739A
(en)
*
|
2006-04-06 |
2008-02-16 |
Novartis Vaccines & Diagnostic |
Quinazolines for PDK1 inhibition
|
US8741643B2
(en)
|
2006-04-28 |
2014-06-03 |
Lifescan, Inc. |
Differentiation of pluripotent stem cells to definitive endoderm lineage
|
DE102006026464A1
(de)
|
2006-06-01 |
2007-12-06 |
Virologik Gmbh Innovationszentrum Medizintechnik Und Pharma |
Pharmazeutische Zusammensetzung zur Behandlung von Virusinfektionen und / oder Tumorerkrankungen durch Inhibition der Proteinfaltung und des Proteinabbaus
|
US7910108B2
(en)
*
|
2006-06-05 |
2011-03-22 |
Incyte Corporation |
Sheddase inhibitors combined with CD30-binding immunotherapeutics for the treatment of CD30 positive diseases
|
DK2041158T3
(da)
|
2006-06-19 |
2013-06-24 |
Onyx Therapeutics Inc |
Peptid-epoxidketoner til proteasom inhibering
|
RU2456990C2
(ru)
*
|
2006-09-15 |
2012-07-27 |
Янссен Фармацевтика Нв |
Комбинации специфичных ингибиторов гистоновых деацетилаз класса i с ингибиторами протеасом
|
EA020276B1
(ru)
*
|
2006-09-15 |
2014-10-30 |
Янссен Фармацевтика Нв |
Ингибиторы гистоновых дезацетилаз с сочетанной активностью в отношении гистоновых дезацетилаз класса i и класса ii в комбинации с ингибиторами протеасом
|
EP2073807A1
(en)
|
2006-10-12 |
2009-07-01 |
Astex Therapeutics Limited |
Pharmaceutical combinations
|
US8916552B2
(en)
|
2006-10-12 |
2014-12-23 |
Astex Therapeutics Limited |
Pharmaceutical combinations
|
AU2007221966A1
(en)
*
|
2006-12-08 |
2008-06-26 |
Centenary Institute Of Cancer Medicine And Cell Biology |
Assay for response to proteasome inhibitors
|
JO3396B1
(ar)
|
2007-06-20 |
2019-10-20 |
Anacor Pharmaceuticals Inc |
جزيئات صغيرة تحتوي على البورون
|
US9080145B2
(en)
*
|
2007-07-01 |
2015-07-14 |
Lifescan Corporation |
Single pluripotent stem cell culture
|
KR101617243B1
(ko)
|
2007-07-31 |
2016-05-02 |
라이프스캔, 인코포레이티드 |
인간 배아 줄기 세포의 분화
|
GB0715087D0
(en)
|
2007-08-03 |
2007-09-12 |
Summit Corp Plc |
Drug combinations for the treatment of duchenne muscular dystrophy
|
JP2010535708A
(ja)
|
2007-08-03 |
2010-11-25 |
ビオマリン アイジーエー リミテッド |
デュシェンヌ型筋ジストロフィーの治療のための薬物併用
|
PT2178888E
(pt)
*
|
2007-08-06 |
2012-10-04 |
Millennium Pharm Inc |
Inibidores do proteassoma
|
US7442830B1
(en)
|
2007-08-06 |
2008-10-28 |
Millenium Pharmaceuticals, Inc. |
Proteasome inhibitors
|
EA034601B1
(ru)
*
|
2007-08-06 |
2020-02-25 |
Милленниум Фармасьютикалз, Инк. |
Способ получения бороновых кислот
|
AU2016253697A1
(en)
*
|
2007-08-06 |
2016-11-24 |
Millennium Pharmaceuticals, Inc. |
Proteasome inhibitors
|
MX2010002836A
(es)
*
|
2007-09-12 |
2010-03-31 |
Reddys Lab Ltd Dr |
Bortezomib y proceso para la produccion del mismo.
|
US20090076031A1
(en)
*
|
2007-09-17 |
2009-03-19 |
Protia, Llc |
Deuterium-enriched bortezomib
|
KR20170125413A
(ko)
|
2007-10-04 |
2017-11-14 |
오닉스 세라퓨틱스, 인크. |
결정형 펩티드 에폭시 케톤 프로테아제 저해제 및 아미노산 케토-에폭시드의 합성
|
US7838673B2
(en)
*
|
2007-10-16 |
2010-11-23 |
Millennium Pharmaceuticals, Inc. |
Proteasome inhibitors
|
US20090110688A1
(en)
*
|
2007-10-24 |
2009-04-30 |
Georg Fertig |
Combination therapy of type ii anti-cd20 antibody with a proteasome inhibitor
|
KR101592182B1
(ko)
*
|
2007-11-27 |
2016-02-05 |
라이프스캔, 인코포레이티드 |
인간 배아 줄기 세포의 분화
|
CN101220048B
(zh)
*
|
2007-12-14 |
2012-08-15 |
江苏先声药物研究有限公司 |
ZnCl2催化下的蒎烷二醇酯的制备方法
|
CA2710122A1
(en)
|
2007-12-20 |
2009-07-02 |
Novartis Ag |
Thiazole derivatives used as pi 3 kinase inhibitors
|
KR101731474B1
(ko)
|
2008-02-21 |
2017-05-11 |
얀센 바이오테크 인코포레이티드 |
세포 부착, 배양 및 탈리를 위한 방법, 표면 개질 플레이트 및 조성물
|
EP3246034A1
(en)
|
2008-03-06 |
2017-11-22 |
Anacor Pharmaceuticals, Inc. |
Boron-containing small molecules as anti-inflammatory agents
|
EP2285384A4
(en)
*
|
2008-05-12 |
2012-04-25 |
Anacor Pharmaceuticals Inc |
BORN SMALL MOLECULES
|
CN103450241A
(zh)
|
2008-06-17 |
2013-12-18 |
米伦纽姆医药公司 |
硼酸酯化合物及其医药组合物
|
PL2942392T3
(pl)
|
2008-06-30 |
2019-02-28 |
Janssen Biotech, Inc |
Różnicowanie pluripotencjalnych komórek macierzystych
|
CN101638414B
(zh)
*
|
2008-07-30 |
2014-01-08 |
江苏先声药物研究有限公司 |
肽硼酸及其酯类化合物、制备方法及其用途
|
US20100028307A1
(en)
*
|
2008-07-31 |
2010-02-04 |
O'neil John J |
Pluripotent stem cell differentiation
|
WO2010027975A1
(en)
*
|
2008-09-04 |
2010-03-11 |
Anacor Pharmaceuticals, Inc. |
Boron-containing small molecules
|
US8461336B2
(en)
|
2008-09-04 |
2013-06-11 |
Anacor Pharmaceuticals, Inc. |
Boron-containing small molecules
|
AR075090A1
(es)
|
2008-09-29 |
2011-03-09 |
Millennium Pharm Inc |
Derivados de acido 1-amino-2-ciclobutiletilboronico inhibidores de proteosoma,utiles como agentes anticancerigenos, y composiciones farmaceuticas que los comprenden.
|
US9493489B2
(en)
*
|
2008-10-15 |
2016-11-15 |
Anacor Pharmaceuticals, Inc. |
Boron-containing small molecules as anti-protozoal agents
|
WO2010048298A1
(en)
|
2008-10-21 |
2010-04-29 |
Proteolix, Inc. |
Combination therapy with peptide epoxyketones
|
CN102333862B
(zh)
|
2008-10-31 |
2018-04-27 |
詹森生物科技公司 |
人胚胎干细胞向胰腺内分泌谱系的分化
|
US9234178B2
(en)
|
2008-10-31 |
2016-01-12 |
Janssen Biotech, Inc. |
Differentiation of human pluripotent stem cells
|
JP5719305B2
(ja)
*
|
2008-11-20 |
2015-05-13 |
ヤンセン バイオテツク,インコーポレーテツド |
平面支持体上での細胞付着及び培養のための方法及び組成物
|
AU2009316580B2
(en)
|
2008-11-20 |
2016-04-14 |
Janssen Biotech, Inc. |
Pluripotent stem cell culture on micro-carriers
|
CN101747354B
(zh)
*
|
2008-12-04 |
2014-08-13 |
江苏先声药物研究有限公司 |
一类β氨基酸组成的二肽硼酸及其酯类化合物、制备方法及其用途
|
JP2012512262A
(ja)
*
|
2008-12-17 |
2012-05-31 |
アナコール ファーマシューティカルズ,インコーポレーテッド |
(s)−3−アミノメチル−7−(3−ヒドロキシ−プロポキシ)−3h−ベンゾ[c][1,2]オキサボロール−1−オールの多形体
|
EA201170921A1
(ru)
|
2009-01-09 |
2012-01-30 |
Сан Фарма Адвансед Ресёрч Компани Лимитед |
Фармацевтическая композиция
|
EP2399129B1
(en)
|
2009-02-20 |
2015-11-25 |
Michael P. Lisanti |
A method of diagnosis or prognosis of a neoplasm comprising determining the level of expression of a protein in stromal cells adjacent to the neoplasm
|
EP2405916B1
(en)
|
2009-03-12 |
2018-02-07 |
Genentech, Inc. |
Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents for the treatment of hematopoietic malignancies
|
AR075899A1
(es)
|
2009-03-20 |
2011-05-04 |
Onyx Therapeutics Inc |
Tripeptidos epoxicetonas cristalinos inhibidores de proteasa
|
WO2010106135A1
(en)
|
2009-03-20 |
2010-09-23 |
Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. |
Combined use for the treatment of ovarian carcinoma
|
PL2411535T3
(pl)
*
|
2009-03-24 |
2015-11-30 |
Janssen Pharmaceutica Nv |
Biomarkery do oceny odpowiedzi zapalnej nerwów obwodowych na leczenie inhibitorem proteasomu
|
WO2010114768A1
(en)
*
|
2009-03-30 |
2010-10-07 |
Cerulean Pharma Inc. |
Polymer-epothilone conjugates, particles, compositions, and related methods of use
|
WO2010114770A1
(en)
*
|
2009-03-30 |
2010-10-07 |
Cerulean Pharma Inc. |
Polymer-agent conjugates, particles, compositions, and related methods of use
|
MX2011010390A
(es)
*
|
2009-03-30 |
2011-12-14 |
Cerulean Pharma Inc |
Conjugados, particulas, composiciones de agentes polimericos y metodos relacionados de uso.
|
CA2763471A1
(en)
*
|
2009-05-27 |
2010-12-02 |
Cephalon, Inc. |
Combination therapy for the treatment of multiple myeloma
|
EP2443128B1
(en)
|
2009-06-19 |
2017-12-20 |
LEK Pharmaceuticals d.d. |
New synthetic route for the preparation of alpha-amino boronic esters
|
EP2270019A1
(en)
|
2009-06-19 |
2011-01-05 |
LEK Pharmaceuticals d.d. |
New synthetic route for the preparation of alpha-amino boronic esters
|
CN101928329B
(zh)
*
|
2009-06-19 |
2013-07-17 |
北京大学 |
三肽硼酸(酯)类化合物、其制备方法和应用
|
EP2280016A1
(en)
|
2009-07-27 |
2011-02-02 |
LEK Pharmaceuticals d.d. |
New synthetic route for the preparation of alpha-amino boronic esters via substituted alk-1-ynes
|
US8293753B2
(en)
|
2009-07-02 |
2012-10-23 |
Novartis Ag |
Substituted 2-carboxamide cycloamino ureas
|
DE102009027754A1
(de)
|
2009-07-15 |
2011-05-05 |
Schubert, Ulrich, Dr. |
Verfahren zur Hemmung der Reifung von dendritischen Zellen
|
MX340952B
(es)
*
|
2009-07-20 |
2016-07-29 |
Janssen Biotech Inc |
Diferenciacion de celulas madre embrionarias humanas.
|
WO2011011300A2
(en)
|
2009-07-20 |
2011-01-27 |
Centocor Ortho Biotech Inc. |
Differentiation of human embryonic stem cells
|
RU2540016C2
(ru)
|
2009-07-20 |
2015-01-27 |
Янссен Байотек, Инк. |
Дифференцировка эмбриональных стволовых клеток человека
|
US8343944B2
(en)
*
|
2009-07-28 |
2013-01-01 |
Anacor Pharmaceuticals, Inc. |
Trisubstituted boron-containing molecules
|
WO2011019618A1
(en)
|
2009-08-14 |
2011-02-17 |
Anacor Pharmaceuticals, Inc. |
Boron-containing small molecules as antiprotozoal agents
|
WO2011022502A1
(en)
|
2009-08-18 |
2011-02-24 |
Georgetown University |
Boronic acid compositions and methods related to cancer
|
MX2012002031A
(es)
*
|
2009-08-19 |
2012-07-04 |
Anacor Pharmaceuticals Inc |
Moleculas pequeñas que contienen boro como agentes antiprotozoarios.
|
CA2770252C
(en)
|
2009-09-08 |
2018-06-12 |
F. Hoffmann-La Roche Ag |
4-substituted pyridin-3-yl-carboxamide compounds and uses thereof for treating cancer
|
WO2011037731A1
(en)
*
|
2009-09-25 |
2011-03-31 |
Anacor Pharmaceuticals, Inc. |
Boron containing small molecules
|
EP2305285A1
(en)
|
2009-09-29 |
2011-04-06 |
Julius-Maximilians-Universität Würzburg |
Means and methods for treating ischemic conditions
|
EP2519231B1
(en)
*
|
2009-10-01 |
2017-03-15 |
Janssen Pharmaceutica NV |
Proteasome inhibitors for treating cancer
|
WO2011049971A1
(en)
|
2009-10-20 |
2011-04-28 |
Anacor Pharmaceuticals, Inc. |
Boron-containing small molecules as antiprotozoal agents
|
WO2011060199A1
(en)
*
|
2009-11-11 |
2011-05-19 |
Anacor Pharmaceuticals, Inc. |
Boron-containing small molecules
|
US8853147B2
(en)
|
2009-11-13 |
2014-10-07 |
Onyx Therapeutics, Inc. |
Use of peptide epoxyketones for metastasis suppression
|
EP2516449A1
(en)
|
2009-12-22 |
2012-10-31 |
Cephalon, Inc. |
Proteasome inhibitors and processes for their preparation, purification and use
|
US9150833B2
(en)
|
2009-12-23 |
2015-10-06 |
Janssen Biotech, Inc. |
Differentiation of human embryonic stem cells
|
SG181685A1
(en)
|
2009-12-23 |
2012-07-30 |
Centocor Ortho Biotech Inc |
Differentiation of human embryonic stem cells
|
WO2011090940A1
(en)
|
2010-01-19 |
2011-07-28 |
Cerulean Pharma Inc. |
Cyclodextrin-based polymers for therapeutic delivery
|
WO2011094450A1
(en)
|
2010-01-27 |
2011-08-04 |
Anacor Pharmaceuticals, Inc |
Boron-containing small molecules
|
RU2607380C2
(ru)
*
|
2010-03-01 |
2017-01-10 |
Янссен Байотек, Инк. |
Способы очистки клеток, производных от плюрипотентных стволовых клеток
|
US9359398B2
(en)
*
|
2010-03-01 |
2016-06-07 |
Onyx Therapeutics, Inc. |
Compounds for immunoproteasome inhibition
|
US8263578B2
(en)
|
2010-03-18 |
2012-09-11 |
Innopharma, Inc. |
Stable bortezomib formulations
|
NZ602392A
(en)
*
|
2010-03-18 |
2014-03-28 |
Innopharma Inc |
Stable bortezomib formulations
|
WO2011116348A1
(en)
|
2010-03-19 |
2011-09-22 |
Anacor Pharmaceuticals, Inc. |
Boron-containing small molecules as anti-protozoal agent
|
ES2625406T3
(es)
|
2010-03-25 |
2017-07-19 |
Oregon Health & Science University |
Glicoproteínas de CMV y vectores recombinantes
|
US8513218B2
(en)
*
|
2010-03-31 |
2013-08-20 |
Millennium Pharmaceuticals, Inc. |
Derivatives of 1-amino-2-cyclopropylethylboronic acid
|
AU2013204868B2
(en)
*
|
2010-03-31 |
2016-10-13 |
Millennium Pharmaceuticals, Inc. |
Derivatives of 1-amino-2-cyclopropylethylboronic acid
|
CN102946729B
(zh)
|
2010-04-07 |
2014-11-05 |
欧尼斯治疗公司 |
结晶肽环氧酮免疫蛋白酶体抑制剂
|
CN101812026B
(zh)
*
|
2010-04-12 |
2013-08-28 |
亚邦医药股份有限公司 |
一种硼替佐米的合成方法
|
EP2560647B1
(en)
|
2010-04-19 |
2016-04-13 |
Niiki Pharma Inc. |
Combination therapy with a proteasome inhibitor and a gallium complex
|
WO2011139379A2
(en)
|
2010-05-06 |
2011-11-10 |
Duke University |
A method of treating patients undergoing protein replacement therapy, gene replacement therapy, or other therapeutic modalities
|
WO2011143299A2
(en)
|
2010-05-12 |
2011-11-17 |
Centocor Ortho Biotech Inc. |
Differentiation of human embryonic stem cells
|
EP2571525A4
(en)
|
2010-05-18 |
2016-04-27 |
Cerulean Pharma Inc |
Compositions and methods for treating autoimmune and other diseases
|
AR082418A1
(es)
|
2010-08-02 |
2012-12-05 |
Novartis Ag |
Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico
|
MX348537B
(es)
|
2010-08-31 |
2017-06-07 |
Janssen Biotech Inc |
Diferencia de celulas madre pluripotentes.
|
US9506036B2
(en)
|
2010-08-31 |
2016-11-29 |
Janssen Biotech, Inc. |
Differentiation of human embryonic stem cells
|
EP3211070A1
(en)
|
2010-08-31 |
2017-08-30 |
Janssen Biotech, Inc. |
Differentiation of human embryonic stem cells
|
US9126997B1
(en)
|
2010-09-07 |
2015-09-08 |
Northwestern University |
Synergistic effect of glucocorticoid receptor agonists in combination with proteosome inhibitors for treating leukemia and myeloma
|
DK2613788T3
(en)
|
2010-09-07 |
2017-08-07 |
Anacor Pharmaceuticals Inc |
BENZOXABOROLD DERIVATIVES FOR TREATMENT OF BACTERIA INFECTIONS
|
EP2624818B1
(en)
|
2010-10-05 |
2017-04-05 |
Fresenius Kabi USA, LLC |
Bortezomib formulations stabilised with boric acid
|
ES2548256T3
(es)
|
2010-10-14 |
2015-10-15 |
Synthon Bv |
Proceso para la preparación de bortezomib y los intermedios para el proceso
|
PL2670753T3
(pl)
|
2011-01-31 |
2017-05-31 |
Novartis Ag |
Nowe pochodne heterocykliczne
|
TW201309303A
(zh)
*
|
2011-03-03 |
2013-03-01 |
Cephalon Inc |
用於治療狼瘡的蛋白酶體抑制劑
|
WO2012135528A2
(en)
|
2011-03-29 |
2012-10-04 |
Texas Tech University System |
Galectin-3c combination therapy for human cancer
|
TWI533885B
(zh)
|
2011-03-31 |
2016-05-21 |
Nanocarrier Co Ltd |
And a pharmaceutical composition comprising a block copolymer containing a boronic acid compound
|
SI2691530T1
(en)
|
2011-06-10 |
2018-08-31 |
Oregon Health & Science University |
CMV glycoproteins and recombinant vectors
|
MX2013015308A
(es)
*
|
2011-06-22 |
2014-05-20 |
Cephalon Inc |
Inhibidores de proteasoma y procesos para su preparacion, purificacion y uso.
|
US8481655B2
(en)
|
2011-07-27 |
2013-07-09 |
Wacker Chemical Corporation |
Copper complexes of amino-functional organosilicon compounds and their use
|
JP6002222B2
(ja)
|
2011-08-11 |
2016-10-05 |
ヤンセン ファーマシューティカ エヌ.ベー. |
がん治療用予測因子
|
WO2013021032A1
(en)
|
2011-08-11 |
2013-02-14 |
Janssen Pharmaceutica Nv |
Histone deacetylase inhibitors in combination with proteasome inhibitors and dexamethasone
|
PT2744332T
(pt)
|
2011-08-19 |
2017-01-24 |
Glaxo Group Ltd |
Compostos de benzofurano para o tratamento de infeções por vírus de hepatite c
|
US9597410B2
(en)
*
|
2011-08-30 |
2017-03-21 |
Trustees Of Tufts College |
FAP-activated proteasome inhibitors for treating solid tumors
|
US20130189754A1
(en)
|
2011-09-12 |
2013-07-25 |
International Aids Vaccine Initiative |
Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
|
US9402894B2
(en)
|
2011-10-27 |
2016-08-02 |
International Aids Vaccine Initiative |
Viral particles derived from an enveloped virus
|
CA2862580A1
(en)
|
2011-10-28 |
2013-05-02 |
Millennium Pharmaceuticals, Inc. |
Biomarkers of response to nae inhibitors
|
MX340452B
(es)
|
2011-10-28 |
2016-07-08 |
Novartis Ag |
Novedosos derivados de purina y su uso en el tratamiento de enfermedades.
|
US20150184246A1
(en)
|
2011-11-11 |
2015-07-02 |
Millennium Pharmaceuticals, Inc. |
Biomarkers of response to proteasome inhibitors
|
CN104039328B
(zh)
|
2011-11-11 |
2018-10-09 |
米伦纽姆医药公司 |
对蛋白酶体抑制剂的反应的生物标记
|
WO2013073697A1
(ja)
|
2011-11-17 |
2013-05-23 |
国立大学法人 東京大学 |
フェニルボロン酸基が導入されたブロックコポリマーおよびその使用
|
RU2705001C2
(ru)
|
2011-12-22 |
2019-11-01 |
Янссен Байотек, Инк. |
Дифференцировка эмбриональных стволовых клеток человека в одногормональные инсулинположительные клетки
|
WO2013110005A1
(en)
|
2012-01-18 |
2013-07-25 |
Wisconsin Alumni Research Foundation |
Boronate-mediated delivery of molecules into cells
|
US9732101B2
(en)
|
2012-01-18 |
2017-08-15 |
Wisconsin Alumni Research Foundation |
Bioreversible boronates for delivery of molecules into cells
|
US20160008382A1
(en)
|
2012-01-24 |
2016-01-14 |
Millennium Pharmaceuticals, Inc. |
Methods of treatment of cancer
|
WO2013112881A1
(en)
|
2012-01-27 |
2013-08-01 |
Thomas Jefferson University |
Mct protein inhibitor-related prognostic and therapeutic methods
|
CN104254544B
(zh)
|
2012-02-08 |
2017-04-26 |
Igm生物科学有限公司 |
Cdim结合蛋白及其用途
|
AU2013227219A1
(en)
|
2012-03-02 |
2014-10-23 |
Dr. Reddy's Laboratories Limited |
Pharmaceutical compositions comprising boronic acid compounds
|
CN104160018A
(zh)
|
2012-03-07 |
2014-11-19 |
詹森生物科技公司 |
用于扩增和维持多能干细胞的成分确定的培养基
|
CA2784240C
(en)
|
2012-03-27 |
2014-07-08 |
Innopharma, Inc. |
Stable bortezomib formulations
|
WO2013173283A1
(en)
|
2012-05-16 |
2013-11-21 |
Novartis Ag |
Dosage regimen for a pi-3 kinase inhibitor
|
ES2690118T3
(es)
|
2012-06-08 |
2018-11-19 |
Janssen Biotech, Inc. |
Diferenciación de células madre embrionarias humanas en células endocrinas pancreáticas
|
EP2679596B1
(en)
|
2012-06-27 |
2017-04-12 |
International Aids Vaccine Initiative |
HIV-1 env glycoprotein variant
|
WO2014011695A2
(en)
|
2012-07-09 |
2014-01-16 |
Onyx Therapeutics, Inc. |
Prodrugs of peptide epoxy ketone protease inhibitors
|
JP2013006855A
(ja)
*
|
2012-09-03 |
2013-01-10 |
Millennium Pharmaceuticals Inc |
プロテアソーム阻害剤
|
WO2014041324A1
(en)
*
|
2012-09-11 |
2014-03-20 |
Cipla Limited |
Process for preparing of bortezamib
|
CN104822844B
(zh)
|
2012-10-01 |
2019-05-07 |
米伦纽姆医药公司 |
预测对抑制剂的反应的生物标记物和方法以及其用途
|
WO2014072985A1
(en)
|
2012-11-06 |
2014-05-15 |
Natco Pharma Limited |
Novel boronic acid derivatives as anti cancer agents
|
US9217001B2
(en)
|
2012-11-16 |
2015-12-22 |
Shilpa Medicare Limited |
Crystalline bortezomib process
|
WO2014097306A1
(en)
|
2012-12-21 |
2014-06-26 |
Natco Pharma Limited |
Stable and pure polymorphic form of bortezomib
|
KR101942769B1
(ko)
|
2012-12-31 |
2019-01-28 |
얀센 바이오테크 인코포레이티드 |
Hb9 조절제를 사용하는 인간 배아 줄기세포의 췌장 내분비 세포로의 분화
|
BR112015015770A2
(pt)
|
2012-12-31 |
2017-07-11 |
Janssen Biotech Inc |
cultivo de células-tronco embrionárias humanas na interface ar-líquido para diferenciação em células pancreáticas endócrinas
|
CA2896750A1
(en)
|
2012-12-31 |
2014-07-03 |
Janssen Biotech, Inc. |
Suspension and clustering of human pluripotent cells for differentiation into pancreatic endocrine cells
|
US10370644B2
(en)
|
2012-12-31 |
2019-08-06 |
Janssen Biotech, Inc. |
Method for making human pluripotent suspension cultures and cells derived therefrom
|
PT2968316T
(pt)
|
2013-03-13 |
2019-10-29 |
Forma Therapeutics Inc |
Derivados de 2-hidroxi-1-{4-[(4-fenilfenil)carbonil]piperazin-1-il}etano-1-ona e compostos relacionados como inibidores da sintase de ácidos gordos (fasn) para o tratamento do cancro
|
US10023611B2
(en)
|
2013-04-16 |
2018-07-17 |
Cipla Limited |
Process for the preparation of bortezomib mannitol ester
|
EP2986290A4
(en)
|
2013-04-19 |
2017-01-04 |
Thomas Jefferson University |
Caveolin-1 related methods for treating glioblastoma with temozolomide
|
US9603775B2
(en)
|
2013-04-24 |
2017-03-28 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
WO2015003146A1
(en)
|
2013-07-03 |
2015-01-08 |
Georgetown University |
Boronic acid derivatives of resveratrol for activating deacetylase enzymes
|
EP2848937A1
(en)
|
2013-09-05 |
2015-03-18 |
International Aids Vaccine Initiative |
Methods of identifying novel HIV-1 immunogens
|
EA201690686A1
(ru)
|
2013-10-03 |
2016-08-31 |
Милленниум Фармасьютикалз, Инк. |
Способ профилактики или лечения системной красной волчанки и/или волчаночного нефрита
|
US10058604B2
(en)
|
2013-10-07 |
2018-08-28 |
International Aids Vaccine Initiative |
Soluble HIV-1 envelope glycoprotein trimers
|
CN104586776B
(zh)
*
|
2013-10-30 |
2017-05-17 |
扬子江药业集团上海海尼药业有限公司 |
以硼替佐米为活性成分的制剂及其制备方法
|
WO2015076359A1
(ja)
*
|
2013-11-21 |
2015-05-28 |
国立大学法人北海道大学 |
プロテアソーム阻害性化合物
|
EP3633381A3
(en)
|
2013-12-05 |
2020-07-29 |
The Broad Institute, Inc. |
Compositions and methods for identifying and treating cachexia or pre-cachexia
|
CA2930359C
(en)
|
2013-12-06 |
2022-03-01 |
Novartis Ag |
Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor
|
US10167311B2
(en)
|
2014-02-03 |
2019-01-01 |
Ohio State Innovation Foundation |
Boronic acid esters and pharmaceutical formulations thereof
|
EP2910557A1
(en)
*
|
2014-02-20 |
2015-08-26 |
Ikerchem, S.L. |
Enantiopure tetrasubstituted pyrrolidines as scaffolds for proteasome inhibitors and medicinal applications thereof
|
US10993960B1
(en)
|
2014-05-08 |
2021-05-04 |
Kawasaki Institute Of Industrial Promotion |
Pharmaceutical composition
|
WO2015175307A1
(en)
|
2014-05-16 |
2015-11-19 |
Janssen Biotech, Inc. |
Use of small molecules to enhance mafa expression in pancreatic endocrine cells
|
UY36132A
(es)
|
2014-05-20 |
2015-11-30 |
Millennium Pharm Inc |
Métodos para terapia de cáncer
|
EP4180041A1
(en)
|
2014-08-07 |
2023-05-17 |
Mayo Foundation for Medical Education and Research |
Compounds and methods for treating cancer
|
US10253049B2
(en)
*
|
2014-10-01 |
2019-04-09 |
Merck Patent Gmbh |
Boronic acid derivatives
|
WO2016110870A1
(en)
|
2015-01-07 |
2016-07-14 |
Emcure Pharmaceuticals Limited |
Pharmaceutical composition of bortezomid
|
MA41505A
(fr)
|
2015-02-11 |
2017-12-19 |
Millennium Pharm Inc |
Nouvelle forme cristalline d'un inhibiteur de protéasome
|
EP3270891A1
(en)
|
2015-03-17 |
2018-01-24 |
Leon-Nanodrugs GmbH |
Nanoparticles comprising a stabilized boronic acid compound
|
US10174292B2
(en)
|
2015-03-20 |
2019-01-08 |
International Aids Vaccine Initiative |
Soluble HIV-1 envelope glycoprotein trimers
|
US9931394B2
(en)
|
2015-03-23 |
2018-04-03 |
International Aids Vaccine Initiative |
Soluble HIV-1 envelope glycoprotein trimers
|
WO2016184793A1
(en)
|
2015-05-15 |
2016-11-24 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for treating a patient with vegfr inhibitor-resistant metastatic renal cell carcinoma
|
WO2016205790A2
(en)
|
2015-06-19 |
2016-12-22 |
Hanlin Scientific, Inc. |
Chiral specific boron-containing compounds and their use in treating cancer or amyloidosis
|
EP3120837A1
(de)
|
2015-07-22 |
2017-01-25 |
Stada Arzneimittel Ag |
Verfahren zur herstellung einer bortezomibester-lösung
|
EP3120836A1
(de)
|
2015-07-22 |
2017-01-25 |
Stada Arzneimittel Ag |
Gebrauchsfertige bortezomib-lösung
|
CN106478700B
(zh)
*
|
2015-08-26 |
2020-12-29 |
杭州雷索药业有限公司 |
硼基取代的苯胺类蛋白激酶抑制剂
|
CN106588965A
(zh)
|
2015-10-15 |
2017-04-26 |
北京大学 |
脲拟肽硼酸化合物及其药物组合物、制备方法和用途
|
WO2017077445A1
(en)
|
2015-11-02 |
2017-05-11 |
Novartis Ag |
Dosage regimen for a phosphatidylinositol 3-kinase inhibitor
|
WO2017106196A1
(en)
|
2015-12-14 |
2017-06-22 |
The Broad Institute, Inc. |
Compositions and methods for treating cardiac dysfunction
|
CN107151255A
(zh)
*
|
2016-03-06 |
2017-09-12 |
复旦大学 |
硼酸类化合物及其制备方法和用途
|
CN107151254A
(zh)
*
|
2016-03-06 |
2017-09-12 |
复旦大学 |
一种作为20s蛋白酶体抑制剂的硼酸类化合物及其制备方法
|
MA45479A
(fr)
|
2016-04-14 |
2019-02-20 |
Janssen Biotech Inc |
Différenciation de cellules souches pluripotentes en cellules de l'endoderme de l'intestin moyen
|
US11447506B2
(en)
|
2016-05-09 |
2022-09-20 |
Anacor Pharmaceuticals, Inc. |
Crystal forms of crisaborole in free form and preparation method and use thereof
|
CN106008572B
(zh)
*
|
2016-05-23 |
2018-08-17 |
成都千禧莱医药科技有限公司 |
一类二肽硼酸化合物及制备方法和用途
|
JP7164521B2
(ja)
|
2016-06-21 |
2022-11-01 |
オリオン・オフサルモロジー・エルエルシー |
炭素環式プロリンアミド誘導体
|
EP4257191A3
(en)
|
2016-06-21 |
2023-11-22 |
Orion Ophthalmology LLC |
Heterocyclic prolinamide derivatives
|
JP6681284B2
(ja)
*
|
2016-06-23 |
2020-04-15 |
信越化学工業株式会社 |
糖アルコール化合物の金属低減方法
|
JP6223508B2
(ja)
*
|
2016-06-27 |
2017-11-01 |
ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. |
プロテアソーム阻害剤
|
WO2018038687A1
(en)
|
2016-08-22 |
2018-03-01 |
Mustafa Nevzat Ilaç Sanayii A.Ş. |
Pharmaceutical formulations comprising a bortezomib-cyclodextrin complex
|
WO2018060833A1
(en)
|
2016-09-27 |
2018-04-05 |
Novartis Ag |
Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib
|
JP2020500839A
(ja)
|
2016-10-20 |
2020-01-16 |
ファイザー・インク |
ペプチドボロン酸またはボロン酸エステル化合物を有する治療用粒子ならびにその作製および使用方法
|
US11584733B2
(en)
|
2017-01-09 |
2023-02-21 |
Shuttle Pharmaceuticals, Inc. |
Selective histone deacetylase inhibitors for the treatment of human disease
|
US11034667B2
(en)
|
2017-01-09 |
2021-06-15 |
Shuttle Pharmaceuticals, Inc. |
Selective histone deacetylase inhibitors for the treatment of human disease
|
EP3583110A1
(en)
|
2017-02-17 |
2019-12-25 |
Fresenius Kabi Oncology Ltd |
An improved process for the preparation of boronic acid esters
|
EP3589659A4
(en)
|
2017-02-28 |
2021-03-24 |
Mayo Foundation for Medical Education and Research |
CANCER TREATMENT COMPOUNDS AND METHODS
|
EP3672586A1
(en)
|
2017-08-23 |
2020-07-01 |
Kezar Life Sciences |
Immunoproteasome inhibitors and immunosuppressive agent in the treatment of autoimmune disorders
|
WO2019053611A1
(en)
|
2017-09-14 |
2019-03-21 |
Glaxosmithkline Intellectual Property Development Limited |
POLY THERAPY FOR THE TREATMENT OF CANCER
|
JP2018024694A
(ja)
*
|
2017-10-03 |
2018-02-15 |
ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. |
プロテアソーム阻害剤
|
DK3710457T3
(da)
*
|
2017-11-16 |
2022-10-24 |
Principia Biopharma Inc |
Immunproteasomhæmmere
|
US11225493B2
(en)
|
2017-11-16 |
2022-01-18 |
Principia Biopharma Inc. |
Immunoproteasome inhibitors
|
US10537585B2
(en)
|
2017-12-18 |
2020-01-21 |
Dexcel Pharma Technologies Ltd. |
Compositions comprising dexamethasone
|
US11407723B2
(en)
|
2018-01-09 |
2022-08-09 |
Shuttle Pharmaceuticals, Inc. |
Selective histone deacetylase inhibitors for the treatment of human disease
|
WO2019148181A1
(en)
|
2018-01-29 |
2019-08-01 |
Cognos Therapeutics, Inc. |
Intratumoral delivery of bortezomib
|
WO2019178438A1
(en)
|
2018-03-15 |
2019-09-19 |
Abbvie Inc. |
Abbv-621 in combination with anti-cancer agents for the treatment of cancer
|
US11243207B2
(en)
|
2018-03-29 |
2022-02-08 |
Mayo Foundation For Medical Education And Research |
Assessing and treating cancer
|
CN113382633A
(zh)
|
2018-10-29 |
2021-09-10 |
福马治疗股份有限公司 |
(4-(2-氟-4-(1-甲基-1H-苯并[d]咪唑-5-基)苯甲酰基)哌嗪-1-基)(1-羟基环丙基)甲酮的固体形式
|
CN109824756B
(zh)
*
|
2019-03-19 |
2022-03-22 |
山东大学 |
含有4-(苯磺酰基)哌嗪-2-酮的苯丙氨酸衍生物及其制备方法与应用
|
CN114437119B
(zh)
*
|
2020-10-30 |
2024-08-09 |
苏州开拓药业股份有限公司 |
一种c-Myc蛋白抑制剂及其制备方法和用途
|
EP4255920A2
(en)
*
|
2020-12-02 |
2023-10-11 |
Hoffman Technologies LLC |
Compositions and methods for modulating cancer in non-human mammals
|
TW202237143A
(zh)
*
|
2020-12-10 |
2022-10-01 |
南韓商Lg化學股份有限公司 |
酸(Boronic Acid)化合物
|
US11964993B2
(en)
|
2021-07-03 |
2024-04-23 |
Shilpa Pharma Lifesciences Limited |
Crystalline bortezomib process
|
EP4134083A1
(en)
|
2021-08-12 |
2023-02-15 |
Extrovis AG |
Pharmaceutical compositions of bortezomib
|
CN113957441B
(zh)
*
|
2021-10-29 |
2024-01-02 |
光华科学技术研究院(广东)有限公司 |
蚀刻液及其制备方法和应用
|
WO2023220641A2
(en)
|
2022-05-11 |
2023-11-16 |
Juno Therapeutics, Inc. |
Methods and uses related to t cell therapy and production of same
|
WO2023220655A1
(en)
|
2022-05-11 |
2023-11-16 |
Celgene Corporation |
Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
|
WO2024097905A1
(en)
|
2022-11-02 |
2024-05-10 |
Celgene Corporation |
Methods of treatment with t cell therapy and immunomodulatory agent maintenance therapy
|